Dalotuzumab_product_DataBase

Bioactivity	Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer drugs such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo[1][2][3].
Invitro	Dalotuzumab (h7C10; 33 nM; 24 h) 抑制 IGF-1 和 IGF-2 诱导的 MCF7 雌激素依赖性乳腺癌细胞增殖，IC50 值分别为 4.2 和 3.1 nM[1]。Dalotuzumab (33 nM; 24 h) 在 IGF-1 诱导的 MCF7 细胞中，诱导周期停滞，并抑制 IGF-IR 和 IRS-1 的自磷酸化[1]。Dalotuzumab 使 NK 细胞介导的 MCF7 和 A459 细胞的裂解率分别提高了 26% 和 25%[1]。Dalotuzumab (MK-0646; 10 µg/mL; 24, 48 h) 消除 IGF1 在子宫内膜癌细胞中的抗凋亡作用[2]。 Cell Proliferation Assay[1] Cell Line:
Name	Dalotuzumab
CAS	1005389-60-5
Molar Mass	146.4 (kDa)
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.

PeptideDB